Elevated NOX4 promotes tumorigenesis and acquired EGFR-TKIs resistance via enhancing IL-8/PD-L1 signaling in NSCLC

• Published in: Drug resistance updates 2023-09, Vol.70, p.100987-100987, Article 100987
• Main Authors: Liu, Wen-Jing, Wang, Lin, Zhou, Feng-Mei, Liu, Shu-Wen, Wang, Wei, Zhao, Er-Jiang, Yao, Quan-Jun, Li, Wei, Zhao, Yan-Qiu, Shi, Zhi, Qiu, Jian-Ge, Jiang, Bing-Hua
• Format: Article
• Language: English
• Subjects: Carcinogenesis; Carcinoma, Non-Small-Cell Lung - drug therapy; Carcinoma, Non-Small-Cell Lung - genetics; Cell Line, Tumor; Drug Resistance, Neoplasm - genetics; ErbB Receptors; Gefitinib - pharmacology; Gefitinib - therapeutic use; Gefitinib resistance; Humans; IL-8; Interleukin-8 - genetics; Lung Neoplasms - drug therapy; Lung Neoplasms - genetics; Mutation; NADPH Oxidase 4 - genetics; NOX4; PD-L1; Tumor growth; Tyrosine Kinase Inhibitors - pharmacology
• ISSN: 1368-7646; 1532-2084
• DOI: 10.1016/j.drup.2023.100987

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have been widely used for human non-small-cell lung cancer (NSCLC) treatment. However, acquired resistance to EGFR-TKIs is the major barrier of treatment success, and new resistance mechanism remains to be elucidated. In this study, we found that elevated NADPH oxidase 4 (NOX4) expression was associated with acquired EGFR-TKIs resistance. Gefitinib is the first-generation FDA-approved EGFR-TKI, and osimertinib is the third-generation FDA-approved EGFR-TKI. We demonstrated that NOX4 knockdown in the EGFR-TKI resistant cells enabled the cells to become sensitive to gefitinib and osimertinib treatment, while forced expression of NOX4 in the sensitive parental cells was sufficient to induce resistance to gefitinib and osimertinib in the cells. To elucidate the mechanism of NOX4 upregulation in increasing TKIs resistance, we found that knockdown of NOX4 significantly down-regulated the expression of transcription factor YY1. YY1 bound directly to the promoter region of IL-8 to transcriptionally activate IL-8 expression. Interestingly, knockdown of NOX4 and IL-8 decreased programmed death ligand 1 (PD-L1) expression, which provide new insight on TKIs resistance and immune escape. We found that patients with higher NOX4 and IL-8 expression levels showed a shorter survival time compared to those with lower NOX4 and IL-8 expression levels in response to the anti-PD-L1 therapy. Knockdown of NOX4, YY1 or IL-8 alone inhibited angiogenesis and tumor growth. Furthermore, the combination of NOX4 inhibitor GKT137831 and gefitinib had synergistic effect to inhibit cell proliferation and tumor growth and to increase cellular apoptosis. These findings demonstrated that NOX4 and YY1 were essential for mediating the acquired EGFR-TKIs resistance. IL-8 and PD-L1 are two downstream targets of NOX4 to regulate TKIs resistance and immunotherapy. These molecules may be used as potential new biomarkers and therapeutic targets for overcoming TKIs resistance in the future. [Display omitted]